There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for DexCom Inc. (DXCM) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.84, or 0.68%, to $123.76. The DexCom Inc. has recorded 142,751 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted What Do Sanofi And Dexcom See In DarioHealth That The Market Is Missing?.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
This NASDAQ-listed company operates within the Medical Devices industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $122.92 and fluctuated between $123.14 as its day high and $119.89 as its day low. The current market capitalization of DexCom Inc. is $46.85B. A total of 2.77 million shares were traded on the day, compared to an average of 2.62M shares.
Insider trades can also provide insight into a stock’s future direction. During the recent three months, DXCM has seen 1 BUY and 7 SELL insider trades, representing the acquisition of 90,720 and the disposition of 114,476 shares. Over the last 12 months, there were 35 BUYs and 82 SELLs from insiders. Insiders purchased 228,475 shares during that period but sold 193,924.
In the most recent transaction, SAYER KEVIN R sold 38,464 shares of DXCM for 109.94 per share on Mar 01. After the transaction, the President CEO and Chairman of now owns 331,337 company shares. In a previous transaction on Feb 23, Pacelli Steven Robert sold 412 shares at 111.64 per share. DXCM shares that EVP Managing Director Dexcom V owns now total 136,464.
Among the insiders who sold shares, Sylvain Jereme M disposed of 2,400 shares on Feb 22 at a per-share price of $114.54. This resulted in the EVP Chief Financial Officer holding 64,837 shares of DXCM after the transaction. In another insider transaction, SAYER KEVIN R sold 56,844 shares at $106.15 per share on Jan 30. Company shares held by the President CEO and Chairman of now total 369,801.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for DXCM in the last 3 months, the mean price target is $132.74 with high estimates of $150.00 and low estimates of $110.00. In terms of 52-week highs and lows, DXCM has a high of $134.76 and a low of $66.89.
As of this writing, DXCM has an earnings estimate of $0.17 per share for the current quarter. EPS was calculated based on a consensus of 10 estimates, with a high estimate of $0.24 per share and a lower estimate of $0.09. The company reported an EPS of $0.28 in the last quarter, which was 16.70% higher than expectations of $0.24.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 22 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DXCM is Sell with a score of 4.67. A total of 14 analysts rated the stock as Buy while 4 rated it as Overweight while 3 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 0 thought it should be Sold.